Who
John P. Brancaccio
Director
Company insider
Files Form 4 as: Director, OKYO Pharma; Chairman, Hepion Pharmaceuticals; Director and Other, Cardiff Oncology; Director, Synergy Pharmaceuticals; Director, Callisto Pharmaceuticals; Director, Tamir Biotechnology.
In numbers
- Trades disclosed
- 149
- Buys
- 12
- Sells
- 1
- Bought
- $166K
- Sold
- $15K
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 31 Dec 2005
- Last trade
- 21 Jul 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Jul 2026filed 7 Aug 2026 | OKYO OKYO PharmaBiotechnology | SEC FORM 4 Bought | $7,3855,000 at $1.48 | filing |
| 21 Jul 2026filed 7 Aug 2026 | OKYO OKYO PharmaBiotechnology | SEC FORM 4 Bought | $7,4005,000 at $1.48 | filing |
| 21 Jul 2026filed 23 Jul 2026 | OKYO OKYO PharmaBiotechnology | SEC FORM 4 Code A | $7,3855,000 at $1.48 | filing |
| 21 Jul 2026filed 23 Jul 2026 | OKYO OKYO PharmaBiotechnology | SEC FORM 4 Code A | $7,4005,000 at $1.48 | filing |
| 8 Jun 2026filed 10 Jun 2026 | OKYO OKYO Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | $12K6,500 at $1.85 | filing |
| 8 Jun 2026filed 10 Jun 2026 | OKYO OKYO Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | $12K6,500 at $1.85 | filing |
| 19 Feb 2024filed 21 Feb 2024 | Hepion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —85,000 at $0.00 | filing |
| 15 Sep 2023filed 28 Sep 2023 | OKYO OKYO PharmaBiotechnology | SEC FORM 4 Bought | $25K16,670 at $1.50 | filing |
| 9 Jun 2022filed 9 Jun 2022 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code J | —26,800 at $0.00 | filing |
| 9 Jun 2022filed 9 Jun 2022 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code J | —22,000 at $0.00 | filing |
| 9 Jun 2022filed 9 Jun 2022 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code J | —28,858 at $0.00 | filing |
| 9 Jun 2022filed 9 Jun 2022 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code J | —44,734 at $0.00 | filing |
| 9 Jun 2022filed 9 Jun 2022 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code J | —755 at $0.00 | filing |
| 9 Jun 2022filed 9 Jun 2022 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code J | —530 at $0.00 | filing |
| 9 Jun 2022filed 9 Jun 2022 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code J | —223 at $0.00 | filing |
| 9 Jun 2022filed 9 Jun 2022 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code J | —223 at $0.00 | filing |
| 9 Jun 2022filed 9 Jun 2022 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code J | —195 at $0.00 | filing |
| 9 Mar 2022filed 10 Mar 2022 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,800 at $0.00 | filing |
| 10 Jun 2021filed 14 Jun 2021 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 18 May 2021filed 20 May 2021 | Hepion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.